Further research on the role of microglia in MS and clinical trials of drugs targeting microglia, either directly (e.g., BTK inhibitors) or indirectly (e.g., frexalimab), may improve outcomes in patients with this debilitating condition. The gene discussed is BTK; the disease is myeloid sarcoma.